YorkBridge Wealth Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

YorkBridge Wealth Partners’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-188	Closed	-$2K	–	808
2018 Q2	$2K	Hold	188	–	–	﹤0.01%	788
2018 Q1	$2K	Hold	188	–	–	﹤0.01%	783
2017 Q4	$2K	Hold	188	–	–	﹤0.01%	805
2017 Q3	$2K	Buy	+188	New	+$2.78K	﹤0.01%	792

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

YorkBridge Wealth Partners's LXRX Position: Q3 2018 in Review

YorkBridge Wealth Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2018, closing a stake of 188 shares — an estimated $2K sold.

YorkBridge Wealth Partners first reported a position in LXRX in Q3 2017 and held it in 4 quarters. The position peaked at $2K in Q2 2018. 119 funds tracked by Wall St. Rank hold LXRX as of Q3 2018.

YorkBridge Wealth Partners reported no remaining Lexicon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
YorkBridge Wealth Partners sold 188 Lexicon Pharmaceuticals shares in Q3 2018, an estimated $2K.
YorkBridge Wealth Partners first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 4 quarters.
YorkBridge Wealth Partners's Lexicon Pharmaceuticals position peaked at $2K in Q2 2018.
119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2018.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.